These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24907635)

  • 21. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
    Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
    J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
    Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
    Uwagawa T; Misawa T; Sakamoto T; Ito R; Gocho T; Shiba H; Wakiyama S; Hirohara S; Sadaoka S; Yanaga K
    Ann Oncol; 2009 Feb; 20(2):239-43. PubMed ID: 18836085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
    Ikeda M; Takahashi H; Kondo S; Lahn MMF; Ogasawara K; Benhadji KA; Fujii H; Ueno H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1169-1177. PubMed ID: 28451833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.
    Cardin DB; Goff LW; Chan E; Whisenant JG; Dan Ayers G; Takebe N; Arlinghaus LR; Yankeelov TE; Berlin J; Merchant N
    Invest New Drugs; 2018 Jun; 36(3):442-450. PubMed ID: 28990119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
    Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
    Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
    Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
    Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
    Xiros N; Papacostas P; Economopoulos T; Samelis G; Efstathiou E; Kastritis E; Kalofonos H; Onyenadum A; Skarlos D; Bamias A; Gogas H; Bafaloukos D; Samantas E; Kosmidis P
    Ann Oncol; 2005 May; 16(5):773-9. PubMed ID: 15802284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
    Zamarin D; Hamid O; Nayak-Kapoor A; Sahebjam S; Sznol M; Collaku A; Fox FE; Marshall MA; Hong DS
    Clin Cancer Res; 2020 Sep; 26(17):4531-4541. PubMed ID: 32586937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
    Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
    Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
    Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
    O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
    Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.